Bio-Techne's stock surged 5.14% during pre-market trading on Wednesday, following the release of its second-quarter fiscal 2026 financial results.

The life sciences company reported adjusted earnings per share of $0.46 for the quarter, beating analyst estimates of $0.43 and representing a 9.5% increase compared to the same period last year. Revenue came in at $295.88 million, also surpassing expectations of $290.19 million.

The strong performance was driven by several key factors, including double-digit growth in its large pharma end-market for the fourth consecutive quarter and ongoing expansion in the China/APAC region for the third straight quarter. The company also achieved an improved adjusted operating margin of 31.1%, supported by productivity initiatives and cost containment measures.